343 related articles for article (PubMed ID: 33106584)
1. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Lozano R; Castro E; Aragón IM; Cendón Y; Cattrini C; López-Casas PP; Olmos D
Br J Cancer; 2021 Feb; 124(3):552-563. PubMed ID: 33106584
[TBL] [Abstract][Full Text] [Related]
2. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitors in Prostate Cancer.
Grewal K; Grewal K; Tabbara IA
Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
[TBL] [Abstract][Full Text] [Related]
4. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
[TBL] [Abstract][Full Text] [Related]
5. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
6. Implications of DNA damage repair alterations for the management of prostate cancer.
Lozano R; Olmos D; Castro E
Curr Opin Urol; 2022 May; 32(3):302-310. PubMed ID: 35266912
[TBL] [Abstract][Full Text] [Related]
7. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
[TBL] [Abstract][Full Text] [Related]
8. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
9. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
Siebert AL; Szymaniak BM; Numan Y; Morgans AK
Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
[TBL] [Abstract][Full Text] [Related]
10. Treatment-emergent neuroendocrine prostate cancer with a germline
Pandya D; Shah M; Kaplan F; Martino C; Levy G; Kazanjian M; Batter S; Martignetti J; Frank RC
Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608381
[TBL] [Abstract][Full Text] [Related]
11. [Homologous recombination deficiency and PARP inhibitors in therapeutics].
Salaün H; Saint-Ghislain M; Bellesoeur A; Beuzeboc P; Neuzillet C; Diéras V; Stern MH; Rodrigues M
Bull Cancer; 2022 Jan; 109(1):76-82. PubMed ID: 34799081
[TBL] [Abstract][Full Text] [Related]
12. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
Saillant A; Flippot R
Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
[No Abstract] [Full Text] [Related]
13. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
14. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
Shah S; Rachmat R; Enyioma S; Ghose A; Revythis A; Boussios S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884434
[TBL] [Abstract][Full Text] [Related]
15. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
16. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
[TBL] [Abstract][Full Text] [Related]
18. Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.
Ghose A; Moschetta M; Pappas-Gogos G; Sheriff M; Boussios S
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575947
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors in ovarian cancer: current status and future promise.
Liu JF; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]